health care provider

BioXcel Therapeutics sNDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based…

The US Centers for Disease Control and Prevention signed off on a recommendation that patients must consult a…

The US Centers for Disease Control and Prevention signed off on a recommendation that patients must consult a…

Maintaining a balanced and nutritious diet has been linked to a number of improved health benefits for years.…

BioXcel Therapeutics BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2…

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease